Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/7/1007 |
| id |
doaj-e14f4febf15b4861907c61bc060642a5 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Anouk Jochems Monique K. van der Kooij Marta Fiocco Maartje G. Schouwenburg Maureen J. Aarts Alexander C. van Akkooi Franchette W.P.J. van den Berkmortel Christian U. Blank Alfonsus J.M. van den Eertwegh Margreet G. Franken JanWillem B. de Groot John B.A.G. Haanen Geke A.P. Hospers Rutger H. Koornstra Wim H.J. Kruit Marieke Louwman Djura Piersma Rozemarijn S. van Rijn Karijn P.M. Suijkerbuijk Albert J. ten Tije Gerard Vreugdenhil Michel W.J.M. Wouters Michiel C.T. van Zeijl Koos J.M. van der Hoeven Ellen Kapiteijn |
| spellingShingle |
Anouk Jochems Monique K. van der Kooij Marta Fiocco Maartje G. Schouwenburg Maureen J. Aarts Alexander C. van Akkooi Franchette W.P.J. van den Berkmortel Christian U. Blank Alfonsus J.M. van den Eertwegh Margreet G. Franken JanWillem B. de Groot John B.A.G. Haanen Geke A.P. Hospers Rutger H. Koornstra Wim H.J. Kruit Marieke Louwman Djura Piersma Rozemarijn S. van Rijn Karijn P.M. Suijkerbuijk Albert J. ten Tije Gerard Vreugdenhil Michel W.J.M. Wouters Michiel C.T. van Zeijl Koos J.M. van der Hoeven Ellen Kapiteijn Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry Cancers uveal melanoma metastatic uveal melanoma survival treatment strategy prognostic factor |
| author_facet |
Anouk Jochems Monique K. van der Kooij Marta Fiocco Maartje G. Schouwenburg Maureen J. Aarts Alexander C. van Akkooi Franchette W.P.J. van den Berkmortel Christian U. Blank Alfonsus J.M. van den Eertwegh Margreet G. Franken JanWillem B. de Groot John B.A.G. Haanen Geke A.P. Hospers Rutger H. Koornstra Wim H.J. Kruit Marieke Louwman Djura Piersma Rozemarijn S. van Rijn Karijn P.M. Suijkerbuijk Albert J. ten Tije Gerard Vreugdenhil Michel W.J.M. Wouters Michiel C.T. van Zeijl Koos J.M. van der Hoeven Ellen Kapiteijn |
| author_sort |
Anouk Jochems |
| title |
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry |
| title_short |
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry |
| title_full |
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry |
| title_fullStr |
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry |
| title_full_unstemmed |
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry |
| title_sort |
metastatic uveal melanoma: treatment strategies and survival—results from the dutch melanoma treatment registry |
| publisher |
MDPI AG |
| series |
Cancers |
| issn |
2072-6694 |
| publishDate |
2019-07-01 |
| description |
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63−14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07−4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients. |
| topic |
uveal melanoma metastatic uveal melanoma survival treatment strategy prognostic factor |
| url |
https://www.mdpi.com/2072-6694/11/7/1007 |
| work_keys_str_mv |
AT anoukjochems metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT moniquekvanderkooij metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT martafiocco metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT maartjegschouwenburg metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT maureenjaarts metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT alexandercvanakkooi metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT franchettewpjvandenberkmortel metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT christianublank metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT alfonsusjmvandeneertwegh metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT margreetgfranken metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT janwillembdegroot metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT johnbaghaanen metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT gekeaphospers metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT rutgerhkoornstra metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT wimhjkruit metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT mariekelouwman metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT djurapiersma metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT rozemarijnsvanrijn metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT karijnpmsuijkerbuijk metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT albertjtentije metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT gerardvreugdenhil metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT michelwjmwouters metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT michielctvanzeijl metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT koosjmvanderhoeven metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry AT ellenkapiteijn metastaticuvealmelanomatreatmentstrategiesandsurvivalresultsfromthedutchmelanomatreatmentregistry |
| _version_ |
1725132762825883648 |
| spelling |
doaj-e14f4febf15b4861907c61bc060642a52020-11-25T01:20:41ZengMDPI AGCancers2072-66942019-07-01117100710.3390/cancers11071007cancers11071007Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment RegistryAnouk Jochems0Monique K. van der Kooij1Marta Fiocco2Maartje G. Schouwenburg3Maureen J. Aarts4Alexander C. van Akkooi5Franchette W.P.J. van den Berkmortel6Christian U. Blank7Alfonsus J.M. van den Eertwegh8Margreet G. Franken9JanWillem B. de Groot10John B.A.G. Haanen11Geke A.P. Hospers12Rutger H. Koornstra13Wim H.J. Kruit14Marieke Louwman15Djura Piersma16Rozemarijn S. van Rijn17Karijn P.M. Suijkerbuijk18Albert J. ten Tije19Gerard Vreugdenhil20Michel W.J.M. Wouters21Michiel C.T. van Zeijl22Koos J.M. van der Hoeven23Ellen Kapiteijn24Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsMedical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6202 AZ Maastricht, The NetherlandsDepartment of Surgical Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDepartment of Medical Oncology, Zuyderland Medical Centre, 6130 MB Sittard-Geleen, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDepartment of Medical Oncology, VU Medical Centre, de Boelelaan 1117, 1081 HZ Amsterdam, The NetherlandsDepartment of Health Technology Assessment, Institute for Medical Technology Assessment and Erasmus School of Health Policy & Management, Erasmus University, Burgemeester Oudlaan 50, 3000 DR Rotterdam, The NetherlandsDepartment of Medical Oncology, Isala Oncological Center, 8000 GK Zwolle, The NetherlandsDepartment of Medical Oncology, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The NetherlandsDepartment of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6500 HB Nijmegen, The NetherlandsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Molewaterplein 40, 3000 CA Rotterdam, The NetherlandsNetherlands Comprehensive Cancer Organisation, PO Box 19079, 3501 DB Utrecht, The NetherlandsDepartment of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The NetherlandsDepartment of Medical Oncology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The NetherlandsDepartment of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The NetherlandsDepartment of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV Breda, The NetherlandsDepartment of Medical Oncology, Maxima Medisch Centrum, de Run 4600, 5500 MB Veldhoven, The NetherlandsDutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsDepartment of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, po box 9600, 2300 RC Leiden, The NetherlandsUveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63−14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07−4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.https://www.mdpi.com/2072-6694/11/7/1007uveal melanomametastatic uveal melanomasurvivaltreatment strategyprognostic factor |